Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Opt Lett ; 48(21): 5639-5642, 2023 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-37910722

RESUMEN

Dissipative quartic solitons have gained interest in the field of mode-locked lasers for their energy-width scaling which allows the generation of ultrashort pulses with high energies. Pursuing the characterization of such pulses, here we found soliton solutions of a distributed model for mode-locked lasers in the presence of either positive or negative fourth-order dispersion (4OD). We studied the impact the laser parameters may have on the profiles, range of existence, and energy-width relation of the output pulses. The most energetic and narrowest solutions occur for negative 4OD, with the energy having an inverse cubic dependence with the width in most cases. Our simulations showed that the spectral filtering has the biggest contribution in the generation of short (widths as low as 39 fs) and very energetic (391 nJ) optical pulses.

2.
Artículo en Inglés | MEDLINE | ID: mdl-37133313

RESUMEN

Summary: Background. Evidence regarding drug provocation test (DPT) with chemotherapeutic agents is scarce. The aim of our study is to describe the experience of DPT in patients with a history of hypersensitivity reactions (HSRs) to antineoplastic and biological agents. Methods. This was an eight-year retrospective, observational, descriptive study of patients with a history of HSRs to chemotherapy who were submitted to DPT. Anamnesis, skin tests (ST) and DPT were analyzed. Patients with a negative DPT were submitted to at least one regular supervised administration (RSA). Patients with positive DPT or HSR during RSA were offered rapid drug desensitization (RDD). Results. A total of 54 patients were submitted to DPT. The most common suspected drugs were platins (n = 36), followed by taxanes (n = 11). Most initial reactions were classified as grade II (n = 39) according to Brown's grading system. ST with platinum (n = 35), taxanes (n = 10) and biological agents (n = 4) were negative, except for one intradermal test with paclitaxel, which was positive. A total of 64 DPTs were performed. Eleven percent of all DPTs were positive (platins (n = 6), doxorubicin (n = 1)). Of the 57 RSA with the culprit drugs, 2 were positive (platins). The diagnosis of hypersensitivity was confirmed by DPT/RSA in 9 patients. All patients with positive DPT/RSA presented HSRs of equal or less severity than the initial one. Conclusions. DPT followed by RSA allowed to exclude HSRs in 45 patients (55 culprit drugs). DPT before desensitization prevents non-hypersensitivity patients from undergoing RDD. In our study DPT was safe, all reactions were managed by an allergist.

3.
Eur Ann Allergy Clin Immunol ; 50(6): 277-280, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-29384113

RESUMEN

Summary: Background. Antiretroviral therapy (ART) may be responsible for hypersensitivity reactions varying in severity, clinical manifestations and frequency. Case report. We report the case of a 47-year-old woman with HIV infection who developed a delayed mucocutaneous reaction after treatment with ART. Hypersensitivty reaction (HR) to emtricitabine and tenofovir was considered probable based on positive patch tests (PT) and hypersensitivity reaction to nevirapine was confirmed by drug provocation test. Discussion. The diagnosis of HR to ART remains a diagnostic challenge, partly due to unknown mechanism and the absence of validated diagnostic tools. Patch testing may represent a useful method for confirming hypersensitivity. Further investigation in this area is required, so that successful management strategies can be offered, preventing loss of potent and viable antiretroviral agents.


Asunto(s)
Fármacos Anti-VIH/inmunología , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/inmunología , Emtricitabina/inmunología , Nevirapina/inmunología , Tenofovir/inmunología , Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/uso terapéutico , Emtricitabina/efectos adversos , Emtricitabina/uso terapéutico , Femenino , Infecciones por VIH/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Nevirapina/efectos adversos , Nevirapina/uso terapéutico , Pruebas Cutáneas , Tenofovir/efectos adversos , Tenofovir/uso terapéutico
4.
Artículo en Inglés | MEDLINE | ID: mdl-24765880

RESUMEN

BACKGROUND AND OBJECTIVE: Drug-induced anaphylaxis is an unpredictable and potentially fatal adverse drug reaction. The aim of this study was to identify the causes of drug-induced anaphylaxis in Portugal. METHODS: During a 4-year period a nationwide notification system for anaphylaxis was implemented, with voluntary reporting by allergists. Data on 313 patients with drug anaphylaxis were received and reviewed. Statistical analysis included distribution tests and multiple logistic regression analysis to investigate significance, regression coefficients, and marginal effects. RESULTS: The mean (SD) age of the patients was 43.8 (17.4) years, and 8.3% were younger than 18 years. The female to male ratio was 2:1.The main culprits were nonsteroidal anti-inflammatory drugs (NSAIDs) (47.9% of cases), antibiotics (35.5%), and anesthetic agents (6.1%). There was a predominance of mucocutaneous symptoms (92.2%), followed by respiratory symptoms (80.4%) and cardiovascular symptoms (49.0%). Patients with NSAID-induced anaphylaxis showed a tendency towards respiratory and mucocutaneous manifestations. We found no significant associations between age, sex, or atopy and type of drug. Anaphylaxis recurrence was observed in 25.6% of cases, and the risk was higher when NSAIDs were involved. CONCLUSIONS: NSAIDs were the most common cause of anaphylaxis in this study and were also associated with a higher rate of recurrence. We stress the need for better therapeutic management and prevention of recurring episodes of drug-induced anaphylaxis.


Asunto(s)
Anafilaxia/inducido químicamente , Anafilaxia/inmunología , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/inmunología , Hipersensibilidad a las Drogas/inmunología , Hipersensibilidad/inmunología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anafilaxia/epidemiología , Niño , Preescolar , Hipersensibilidad a las Drogas/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Portugal/epidemiología , Adulto Joven
5.
Eur Ann Allergy Clin Immunol ; 46(1): 53-5, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24702878

RESUMEN

Clopidogrel is an antiplatelet drug widely used for treatment and prevention of a variety of cardiovascular diseases. We report a successful desensitization to clopidogrel in a 70-year-old Caucasian man with delayed hypersensitivity (HS) reaction. He developed lip, hand and foot swelling, erythematous papular non-pruritic lesions and arthralgias 2 weeks after starting treatment with clopidogrel 75 mg/d. A 3-hour desensitization protocol was started, achieving a cumulative dose of 154 mg without any reaction, and a daily dose of 75 mg was recommended. On the 4th day, the patient developed skin lesions similar to the previously described. He was treated with topical steroids and oral antihistamines, and the daily dose of clopidogrel was reduced to 20 mg. A new desensitization protocol was established, with a slow dose increment, according to the patient's response. It was only possible to achieve the dose of 75 mg/d after 2 months. Although well tolerated by most patients, HS reactions with clopidogrel may occur and desensitization is rising as a safe alternative in those patients. In delayed reactions with cutaneous lesions, a slower desensitization protocol may be necessary, as in this case.


Asunto(s)
Desensibilización Inmunológica , Hipersensibilidad a las Drogas/terapia , Inhibidores de Agregación Plaquetaria/efectos adversos , Ticlopidina/análogos & derivados , Anciano , Clopidogrel , Humanos , Masculino , Ticlopidina/efectos adversos
7.
J. investig. allergol. clin. immunol ; 24(1): 40-48, ene.-feb. 2014. tab, ilus
Artículo en Inglés | IBECS (España) | ID: ibc-119153

RESUMEN

Background and Objective: Drug-induced anaphylaxis is an unpredictable and potentially fatal adverse drug reaction. The aim of this study was to identify the causes of drug-induced anaphylaxis in Portugal. Methods: During a 4-year period a nationwide notification system for anaphylaxis was implemented, with voluntary reporting by allergists. Data on 313 patients with drug anaphylaxis were received and reviewed. Statistical analysis included distribution tests and multiple logistic regression analysis to investigate significance, regression coefficients, and marginal effects. Results: The mean (SD) age of the patients was 43.8 (17.4) years, and 8.3% were younger than 18 years. The female to male ratio was 2:1. The main culprits were nonsteroidal anti-inflammatory drugs (NSAIDs) (47.9% of cases), antibiotics (35.5%), and anesthetic agents (6.1%). There was a predominance of mucocutaneous symptoms (92.2%), followed by respiratory symptoms (80.4%) and cardiovascular symptoms (49.0%). Patients with NSAID-induced anaphylaxis showed a tendency towards respiratory and mucocutaneous manifestations. We found no significant associations between age, sex, or atopy and type of drug. Anaphylaxis recurrence was observed in 25.6% of cases, and the risk was higher when NSAIDs were involved. Conclusions: NSAIDs were the most common cause of anaphylaxis in this study and were also associated with a higher rate of recurrence. We stress the need for better therapeutic management and prevention of recurring episodes of drug-induced anaphylaxis (AU)


Antecedentes: La anafilaxia inducida por medicamentos es una reacción adversa impredecible y potencialmente fatal. El objetivo de este estudio fue identificar las causas de la misma en Portugal. Método: Durante un periodo de 4 años fue desarrollado un sistema de notificación nacional de anafilaxia enfocado al informe voluntario de los alergólogos. Se recopilaron 313 casos de pacientes con anafilaxia por medicamentos. El análisis estadístico incluyó test de distribución y regresión logística múltiple para analizar la significación y los coeficientes de regresión y efectos marginales. Resultados: La edad media de los pacientes fue de 43.8 ± 17.4 años, 8.3% menores de 18 años. La relación mujer/varón fue de 2:1. El grupo más frecuentemente implicado fue el de los analgésicos antiinflamatorios no esteroideos (AINEs), seguido de los antibióticos y anestésicos en 47.9%, 35.5% y 6.1% de los casos respectivamente. Se observó un predominio de los síntomas mucocutáneos (92.2%), seguidos de los respiratorios (80.4%) y cardiovasculares (49.0%). Los pacientes con anafilaxia por AINEs mostraban más síntomas respiratorios y mucocutáneos. No se encontró asociación entre edad, género y atopia con los diferentes grupos de medicamentos. La recurrencia de anafilaxia se observó en el 25.6% de los casos, con un riesgo incrementado cuando los AINEs eran los responsables. Conclusiones: En este estudio, los AINEs fueron los medicamentos más frecuentemente implicados en las reacciones de anafilaxia y mostraron más frecuencia de reincidencia de las reacciones. Es importante evaluar bien los tratamientos y prevenir la reincidencia de anafilaxia por medicamentos (AU)


Asunto(s)
Humanos , Anafilaxia/inducido químicamente , Hipersensibilidad a las Drogas/epidemiología , Portugal/epidemiología , Encuestas Epidemiológicas , Notificación de Enfermedades , Sistemas de Registro de Reacción Adversa a Medicamentos/organización & administración
8.
Allergol Immunopathol (Madr) ; 33(5): 285-7, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16287549

RESUMEN

BACKGROUND: Nimesulide is a cyclooxygenase (COX) inhibitor with a high degree of selectivity to COX-2. It is a widely used and well tolerated nonsteroidal antiinflammatory drug that also has analgesic and antipyretic properties. The most frequently reported side effects concern the gastrointestinal tract. Pruritus and skin rash are the most common cutaneous adverse reactions. There are only eight cases of fixed drug eruptions due to nimesulide, described in the literature. CASE REPORT: The authors report a case of a patient with a history of antihistamine hypersensitivity who developed a bullous form of pigmented fixed drug eruption after nimesulide ingestion. Patch tests performed on residual skin lesion were positive to nimesulide, confirming that this was the culprit drug. CONCLUSIONS: Fixed drug eruptions are common cutaneous drug reactions, often misdiagnosed. A detailed anamnesis and physical examination are the key to suspect this condition.


Asunto(s)
Erupciones por Medicamentos/etiología , Sulfonamidas/efectos adversos , Acetaminofén/administración & dosificación , Adulto , Bromofeniramina/administración & dosificación , Bromofeniramina/efectos adversos , Cafeína/administración & dosificación , Claritromicina/efectos adversos , Combinación de Medicamentos , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Antagonistas de los Receptores Histamínicos H1/efectos adversos , Humanos , Masculino , Piperazinas/efectos adversos , Método Simple Ciego , Pruebas Cutáneas , Síndrome de Stevens-Johnson/etiología , Urticaria/inducido químicamente
9.
Allergol Immunopathol (Madr) ; 33(6): 329-32, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16371221

RESUMEN

BACKGROUND: Corticosteroids (CS) are widely used in the treatment of asthma, allergic disorders and other immunological diseases due to their anti-inflammatory and immunosuppressive properties. Physicians seldom suspect them of causing allergic reactions. However, more and more cases of hypersensitivity reactions to CS have been described. Reports of delayed allergic reactions to CS in patients with asthma or allergic rhinitis are scarce. MATERIAL AND METHODS: We report the case of a 44-year-old woman with a history of mild persistent asthma and intermittent allergic rhinitis, treated with inhaled beclomethasone and salbutamol, who developed a delayed mucocutaneous and respiratory reaction after substitution of beclomethasone with budesonide. CONCLUSIONS: The interest of this case lies in the rarity of allergic reactions from inhaled CS in patients with asthma and/or rhinitis. These reactions therefore represent a diagnostic and therapeutic challenge.


Asunto(s)
Antialérgicos/efectos adversos , Antiasmáticos/efectos adversos , Budesonida/efectos adversos , Hipersensibilidad a las Drogas/etiología , Hipersensibilidad Tardía/inducido químicamente , Administración por Inhalación , Corticoesteroides/efectos adversos , Adulto , Albuterol/administración & dosificación , Albuterol/uso terapéutico , Antialérgicos/administración & dosificación , Antialérgicos/uso terapéutico , Antiasmáticos/administración & dosificación , Antiasmáticos/uso terapéutico , Asma/complicaciones , Asma/tratamiento farmacológico , Beclometasona/administración & dosificación , Beclometasona/uso terapéutico , Budesonida/administración & dosificación , Budesonida/uso terapéutico , Reacciones Cruzadas , Erupciones por Medicamentos/etiología , Quimioterapia Combinada , Femenino , Humanos , Pruebas del Parche , Rinitis Alérgica Perenne/complicaciones , Rinitis Alérgica Perenne/tratamiento farmacológico , Pruebas Cutáneas
11.
Zentralbl Bakteriol Orig A ; 241(3): 384-7, 1978 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-569412

RESUMEN

29 Patients of ages varying from 12 to 60 years were treated orally with doses of 0.07 g/kg body weight of ethereal extract of male-fern, preceded by the administration of hypertonic solution of magnesium sulphate (15 g in 200 ml of water). All of them were previously treated with other anthelminthics without success. 25 of the patients obtained total cure. One woman expelled 14 scoleces of T. solium. The species determination for the 29 cases of Taeniasis revealed 3 cases of T. solium (10.3%) and 26 cases of T. saginata (89.7%).


Asunto(s)
Antihelmínticos/administración & dosificación , Sulfato de Magnesio/administración & dosificación , Plantas Medicinales , Teniasis/tratamiento farmacológico , Administración Oral , Adolescente , Adulto , Niño , Quimioterapia Combinada , Heces/parasitología , Femenino , Humanos , Soluciones Hipertónicas , Masculino , Persona de Mediana Edad , Extractos Vegetales
16.
Allergol. immunopatol ; 37(1): 50-51, ene. 2009. ilus, tab
Artículo en Inglés | IBECS (España) | ID: ibc-115935

RESUMEN

No disponible


No disponible


Asunto(s)
Humanos , Masculino , Femenino , Hipersensibilidad a las Drogas
17.
Allergol. immunopatol ; 33(6): 329-332, nov. 2005. ilus, tab
Artículo en En | IBECS (España) | ID: ibc-044237

RESUMEN

Background: Corticosteroids (CS) are widely used in the treatment of asthma, allergic disorders and other immunological diseases due to their anti-inflammatory and immunosuppressive properties. Physicians seldom suspect them of causing allergic reactions. However, more and more cases of hypersensitivity reactions to CS have been described. Reports of delayed allergic reactions to CS in patients with asthma or allergic rhinitis are scarce. Material and methods: We report the case of a 44-year-old woman with a history of mild persistent asthma and intermittent allergic rhinitis, treated with inhaled beclomethasone and salbutamol, who developed a delayed mucocutaneous and respiratory reaction after substitution of beclomethasone with budesonide. Conclusions: The interest of this case lies in the rarity of allergic reactions from inhaled CS in patients with asthma and/or rhinitis. These reactions therefore represent a diagnostic and therapeutic challenge


No disponible


Asunto(s)
Femenino , Adulto , Humanos , Antialérgicos/efectos adversos , Antiasmáticos/efectos adversos , Budesonida/efectos adversos , Hipersensibilidad a las Drogas/etiología , Hipersensibilidad Tardía/inducido químicamente , Corticoesteroides/efectos adversos , Corticoesteroides , Albuterol/administración & dosificación , Albuterol/uso terapéutico , Antialérgicos/administración & dosificación , Antiasmáticos/administración & dosificación , Asma/complicaciones , Asma/tratamiento farmacológico , Beclometasona/administración & dosificación , Beclometasona/uso terapéutico , Budesonida/administración & dosificación , Reacciones Cruzadas , Erupciones por Medicamentos/etiología , Rinitis Alérgica Perenne/complicaciones , Rinitis Alérgica Perenne/tratamiento farmacológico
18.
Allergol. immunopatol ; 33(5): 285-287, sept. 2005. ilus
Artículo en En | IBECS (España) | ID: ibc-042140

RESUMEN

Background: Nimesulide is a cyclooxygenase (COX) inhibitor with a high degree of selectivity to COX-2. It is a widely used and well tolerated nonsteroidal antiinflammatory drug that also has analgesic and antipyretic properties. The most frequently reported side effects concern the gastrointestinal tract. Pruritus and skin rash are the most common cutaneous adverse reactions. There are only eight cases of fixed drug eruptions due to nimesulide, described in the literature. Case report: The authors report a case of a patient with a history of antihistamine hypersensitivity who developed a bullous form of pigmented fixed drug eruption after nimesulide ingestion. Patch tests performed on residual skin lesion were positive to nimesulide, confirming that this was the culprit drug. Conclusions: Fixed drug eruptions are common cutaneous drug reactions, often misdiagnosed. A detailed anamnesis and physical examination are the key to suspect this condition


No disponible


Asunto(s)
Masculino , Adulto , Humanos , Erupciones por Medicamentos/etiología , Combinación de Medicamentos , Sulfonamidas/efectos adversos , Urticaria/inducido químicamente , Acetaminofén/administración & dosificación , Bromofeniramina/efectos adversos , Bromofeniramina , Cafeína/administración & dosificación , Claritromicina/efectos adversos , Claritromicina , Antagonistas de los Receptores Histamínicos H1/efectos adversos , Piperazinas/efectos adversos , Piperazinas , Método Simple Ciego
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA